Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Junghans, U.
Right arrow Articles by Siebler, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Junghans, U.
Right arrow Articles by Siebler, M.
Related Collections
Right arrow MRI
Right arrow All Cerebrovascular disease/Stroke
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrow Infarction
Neurology 2002;58:474-476
© 2002 American Academy of Neurology
Brief Communications

Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban

U. Junghans, MD, R. J. Seitz, MD, A. Ritzl, PhD, H.-J. Wittsack, PhD, G. R. Fink, MD, H.-J. Freund, MD and M. Siebler, MD

From the Department of Neurology (Drs. Junghans, Seitz, Ritzl, Fink, Freund, and Siebler) and Institute of Diagnostic Radiology (Dr. Wittsack), University Hospital Düsseldorf, Germany.

Address correspondence and reprint requests to Prof. Dr. M. Siebler, Department of Neurology, University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany; e-mail: siebler{at}uni-duesseldorf.de

In an open pilot study, the authors tested whether the nonpeptide glycoprotein (GP) IIb/IIIa antagonist tirofiban, a highly effective and selective blocker of platelet aggregation, prevents the transition of ischemic brain tissue into the infarct proper as defined by MRI (perfusion-weighted/T2-weighted) in patients with acute ischemic stroke. The infarct volume (T2 lesion after 1 week) was smaller in treated patients (n = 10) compared with matched control subjects (n = 10; p = 0.029) with similar initial perfusion deficit (TTP-maps). The authors conclude that GP IIb/IIIa antagonists have therapeutic potential in acute stroke therapy.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.